Frontlight ResearchEarly access
WithdrawnPhase 2
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
Key facts
- Who runs it
- Rivus Pharmaceuticals, Inc.
- Where
- Orlando, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 17 Nov 2023
- Ended
- Mar 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- HU6
- Record updated
- 9 January 2024
- Why it stopped
- The protocol was redirected by the FDA to another division and will be resubmitted at a future date.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Able to understand the procedures and requirements of the study and provide written informed consent and authorization for protected health information disclosure
- Willing and able to comply with the requirements of the study protocol
- Male or female 18 to 70 years of age, inclusive, at time of informed consent
- Body mass index (BMI) >28.0 kg/m2 and able to fit into the MRI machine
- Subject has T2D meeting all of the following criteria:
Who cannot take part
- Subject-reported history of weight gain or loss >5% in 3 months prior to screening
- Body weight >450 pounds
- The subject participates in programmed exercise >3 hours per week
Where in United States
- AdventHealth Translational Research InstituteOrlando, United States
About the trial
What the trial wants to find out
This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D.
Read full original descriptionShow less
The study will be conducted in 4 stages.
The 2 groups in the trial
- Active Treatment HU6Treatment being tested
Subjects who are randomized to active study drug will receive 450mg of HU6 for 14 day and then 600mg of HU6 for 168 days. N = 24
Treatment: HU6
- PlaceboPlacebo, for comparison
Placebo Comparator is non-active study drug. N = 24
Treatment: HU6
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2a Study of the Effects of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
- Record updated
- 9 January 2024